Ypsomed spends $248M to gain its first US manufacturing site news2025-10-10T10:50:38+00:00October 10th, 2025|Endpoints News|
Chinese biotechs work on cheaper alternatives to $2M Zolgensmanews2025-10-09T14:00:08+00:00October 9th, 2025|Endpoints News|
Colorado drug board sets first state pricing limit for Amgen’s Enbrel in 2027news2025-10-08T17:41:32+00:00October 8th, 2025|Endpoints News|
UK drafts plans to pay up to 25% more for meds to appease drugmakersnews2025-10-08T17:10:21+00:00October 8th, 2025|Endpoints News|
Lawyers scramble on how to advise clients on Trump’s 100% pharma tariff threat news2025-10-08T16:13:10+00:00October 8th, 2025|Endpoints News|
Dimerix says observational analysis could back speedier path to market for rare kidney disease drugnews2025-10-08T11:09:39+00:00October 8th, 2025|Endpoints News|
FDA approves Boehringer Ingelheim’s idiopathic pulmonary fibrosis pillnews2025-10-07T19:19:59+00:00October 7th, 2025|Endpoints News|
Third Circuit appeals court tosses Novo Nordisk’s IRA case news2025-10-07T19:11:42+00:00October 7th, 2025|Endpoints News|
GLP-1 coverage update from CMS coming ‘very soon,’ Oz saysnews2025-10-07T17:49:27+00:00October 7th, 2025|Endpoints News|
